Record-Breaking Price Performance
On 13 Mar 2026, Venus Remedies Ltd touched an intraday peak of Rs.946.1, setting a fresh 52-week and all-time high benchmark for the stock. Despite closing the day with a decline of 4.58%, the stock demonstrated significant resilience by trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical strength reflects a bullish trend that was officially confirmed on 12 Mar 2026 when the trend shifted from mildly bullish to bullish at a price of Rs.927.5.
The stock exhibited high volatility during the trading session, with an intraday volatility of 39.34%, fluctuating between a low of Rs.900.25 and the record high. While the day’s performance underperformed the sector by 1.91% and the Sensex by 3.95 percentage points, the broader trend remains strongly positive.
Impressive Long-Term Returns Outperforming Benchmarks
Venus Remedies Ltd’s price appreciation over various time horizons has been remarkable. The stock has delivered a staggering 855.72% return over the past decade, vastly outperforming the Sensex’s 205.68% gain during the same period. Over five years, the stock surged 274.21% compared to the Sensex’s 48.76%, and in the last three years, it soared 440.13% against the benchmark’s 29.74%.
More recently, the company’s one-year return stands at 200.31%, dwarfing the Sensex’s modest 2.34% increase. Even year-to-date, Venus Remedies has gained 15.38%, contrasting with the Sensex’s decline of 11.34%. The one-month and three-month performances also reflect strong momentum, with gains of 19.76% and 7.52% respectively, while the Sensex declined by 8.56% and 11.39% over the same periods.
Robust Financial Metrics Underpinning Growth
The company’s financial health supports its market performance. Venus Remedies reported a 96.37% growth in operating profit in the December 2025 quarter, accompanied by a 116.9% increase in quarterly PAT, which stood at Rs.25.58 crores. The company has consistently declared positive results for five consecutive quarters, signalling operational strength and effective management.
Return on Capital Employed (ROCE) reached a high of 13.99% in the half-year period, while the inventory turnover ratio peaked at 6.58 times, indicating efficient asset utilisation. The company’s Return on Equity (ROE) is a fair 10.5%, supported by a low average debt-to-equity ratio of zero, highlighting a net cash position and a strong balance sheet.
Valuation multiples as of 13 Mar 2026 show a Price-to-Earnings (P/E) ratio of 16x and a Price-to-Book Value (P/BV) of 2.09x. The PEG ratio is notably low at 0.09x, reflecting the company’s earnings growth relative to its price. Enterprise Value to EBITDA stands at 9.02x, while EV to Capital Employed is 2.73x, suggesting reasonable valuation metrics for a micro-cap stock.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Institutional Participation and Market Capitalisation
Institutional investors have increased their stake by 0.67% over the previous quarter, now collectively holding 3.28% of the company’s shares. This gradual increase in institutional ownership reflects confidence in the company’s fundamentals and governance. Venus Remedies is classified as a micro-cap stock, which often presents unique growth opportunities and volatility characteristics.
Technical Indicators and Trading Volumes
Technical analysis reveals a predominantly bullish outlook. Weekly and monthly Bollinger Bands are bullish, and moving averages support the upward trend. Some indicators such as MACD and KST show mild bearishness on a weekly basis but remain bullish monthly, indicating short-term fluctuations within a longer-term positive trend.
Delivery volumes have surged significantly, with a 473.0% increase over the past month and a 168.62% rise in one-day delivery compared to the five-day average. On 12 Mar 2026, delivery volume reached 87.96 thousand shares, accounting for 38.85% of total volume, well above the trailing one-month average of 14.05 thousand shares.
Quality Assessment and Capital Structure
Venus Remedies holds an average quality grade based on long-term financial performance. The company benefits from an excellent capital structure with minimal debt, reflected in an average debt-to-EBITDA ratio of 0.63 and a strong interest coverage ratio of 37.06x. It is a net cash company with no promoter share pledging, reinforcing financial stability.
However, growth metrics show some moderation, with a five-year sales growth rate of 6.29% and an EBIT growth of 29.54%. Average ROCE and ROE over the long term are relatively weak at 7.85% and 7.52% respectively, though recent half-year figures indicate improvement.
Thinking about Venus Remedies Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Summary of Key Valuation and Performance Metrics
As of 13 Mar 2026, Venus Remedies Ltd trades at Rs.885.00, just 6.46% below its all-time high. The stock’s 52-week low was Rs.277.85, indicating a substantial appreciation of over 218% from the low point. The company’s dividend yield is not available, with the last dividend declared at Rs.3 per share in September 2013.
The stock’s Price-to-Earnings ratio of 16x and EV/EBITDA of 9.02x suggest a valuation that balances growth with reasonable multiples. The PEG ratio of 0.09x highlights the company’s earnings growth relative to its price, signalling efficient value creation over the recent period.
Concluding Observations on the Milestone Achievement
Venus Remedies Ltd’s ascent to an all-time high of Rs.946.1 represents a significant milestone in its market journey, reflecting strong financial results, improving operational metrics, and sustained investor confidence. The company’s ability to outperform the Sensex and its sector peers across multiple timeframes underscores its competitive positioning within the Pharmaceuticals & Biotechnology sector.
While the stock experienced a short-term pullback after seven consecutive days of gains, its overall trend remains bullish, supported by solid fundamentals and technical indicators. The company’s low debt profile, consistent profit growth, and efficient capital utilisation contribute to its robust market valuation and quality grade.
Investors and market participants will note the stock’s high volatility and trading volume spikes, which are characteristic of micro-cap stocks but also indicative of active market interest and liquidity.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
